Phreesia (PHR) to Release Earnings on Monday

Phreesia (NYSE:PHR) is expected to announce its Q3 2026 results after the market closes on Monday, December 8th. Analysts expect Phreesia to post earnings of ($0.01) per share and revenue of $119.98 million for the quarter. Phreesia has set its FY 2026 guidance at EPS.Investors can check the company’s upcoming Q3 2026 earningsummary page for the latest details on the call scheduled for Monday, December 8, 2025 at 5:00 PM ET.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. The company had revenue of $117.26 million during the quarter, compared to analysts’ expectations of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.During the same period in the prior year, the company earned ($0.03) EPS. Phreesia’s revenue was up 14.9% compared to the same quarter last year. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Price Performance

Shares of PHR opened at $20.50 on Monday. The business has a 50-day simple moving average of $22.45 and a two-hundred day simple moving average of $25.45. Phreesia has a 12-month low of $18.55 and a 12-month high of $32.76. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.23 billion, a PE ratio of -48.80 and a beta of 0.74.

Insider Activity

In other Phreesia news, CFO Balaji Gandhi sold 4,183 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $97,380.24. Following the sale, the chief financial officer owned 99,125 shares in the company, valued at $2,307,630. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Evan Roberts sold 3,761 shares of Phreesia stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $87,556.08. Following the completion of the transaction, the insider owned 726,837 shares of the company’s stock, valued at approximately $16,920,765.36. This trade represents a 0.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 26,174 shares of company stock valued at $603,835. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Dark Forest Capital Management LP increased its position in shares of Phreesia by 217.5% during the third quarter. Dark Forest Capital Management LP now owns 23,410 shares of the company’s stock valued at $551,000 after buying an additional 16,037 shares during the period. PharVision Advisers LLC bought a new position in shares of Phreesia in the third quarter valued at approximately $345,000. Virtus Advisers LLC grew its stake in Phreesia by 522.8% during the third quarter. Virtus Advisers LLC now owns 14,181 shares of the company’s stock valued at $334,000 after acquiring an additional 11,904 shares in the last quarter. Sherbrooke Park Advisers LLC increased its holdings in Phreesia by 18.0% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 20,425 shares of the company’s stock worth $480,000 after acquiring an additional 3,119 shares during the period. Finally, Qube Research & Technologies Ltd lifted its stake in Phreesia by 87.4% in the 3rd quarter. Qube Research & Technologies Ltd now owns 730,054 shares of the company’s stock worth $17,171,000 after purchasing an additional 340,535 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Phreesia from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, September 5th. Piper Sandler increased their price target on Phreesia from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Friday, September 5th. KeyCorp reduced their target price on Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, October 8th. Citigroup restated an “outperform” rating on shares of Phreesia in a report on Monday, September 8th. Finally, Truist Financial increased their price objective on Phreesia from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.71.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.